Nano-Sized Particle NSAIDs Effective for Peak Pain Relief
Nano-sized drug particle NSAIDs could be effective in the management of pain and warrant further evaluation, according a presentation at PAINWeek 2012.
Nano-sized drug particle NSAIDs could be effective in the management of pain and warrant further evaluation, according a presentation at PAINWeek 2012.
An orally inhaled dihydroergotamine studied for the rescue treatment of acute migraine exhibited significant pain relief compared with placebo, according to the results of a pivotal phase 3 trial presented at PAINWeek 2012
An analysis of tapentadol immediate-release showed it may offer an effective pain management option for post-operative hospitalized patients, as reported at PAINWeek 2012.
Fentanyl buccal tablets have been shown to provide a more rapid onset of analgesia than immediate-release oxycodone for the relief of breakthrough back pain, as reported at PAINWeek 2012.
Larry Dillaha, MD, of INSYS Therapeutics, Phoenix, AZ, and colleagues reported at PAINWeek 2012 that fentanyl sublingual spray markedly improved satisfaction with symptom relief among patients with breakthrough cancer pain (BTCP).
A study comparing tapentadol immediate-release and oxycodone immediate-release in moderate-to-severe, acute low back pain with radicular leg pain demonstrated comparable efficacy, with reduced gastrointestinal side effects seen with the tapentadol immediate-release arm, investigators reported during PAINWeek 2012.
Emilee Connors, PhD, of MAP Pharmaceuticals, Mountain View, CA, and colleagues reported at PAINWeek 2012 that the inhaled, investigational drug MAP0004 provided consistent and similar response rates for episodic migraine attacks even after repeated administration.
Vincent Brett, MS, PharmD, of Janssen Scientific Affairs, Raritan, NJ, and colleagues presented a post-hoc analysis of pooled safety data at PAINWeek 2012, and found that adding tapentadol to selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) resulted in no clinically relevant adverse drug interactions.
Please login or register first to view this content.